Table 1.
Clinical and pathological features of men with M0 CRPC by BMI group
| Underweight BMI <21 kg/m2 |
Normal Weight BMI 21–24.9 kg/m2 |
Overweight BMI 25–29.9 kg/m2 |
Obese BMI ≥30 kg/m2 |
p-value | |
|---|---|---|---|---|---|
| No. patients, n (%) | 51 (4) | 239 (20) | 464 (39) | 438 (37) | - |
| BMI (kg/m2), Median (Q1–Q3) | 20.0 (19.0–20.6) | 23.7 (22.7–24.3) | 27.5 (26.3–28.8) | 33.7 (31.5–37.1) | - |
| Age, Median (Q1–Q3) | 79 (71–87) | 80 (73–85) | 77 (70–83) | 73 (66–79) | <0.001K |
| Race, n (%) | 0.209C | ||||
| Non-black | 32 (63) | 172 (72) | 349 (75) | 312 (71) | |
| Black | 19 (37) | 67 (28) | 115 (25) | 126 (29) | |
| Year of CRPC, Median (Q1–Q3) | 2009 (2004–2011) | 2006 (2004–2009) | 2006 (2003–2010) | 2008 (2005–2011) | <0.001 K |
| Primary Localized Treatment | 0.011C | ||||
| None | 28 (55) | 109 (46) | 222 (48) | 165 (38) | |
| Radical Prostatectomy ± Radiation | 8 (16) | 41 (17) | 93 (20) | 114 (26) | |
| Radiation Alone | 15 (29) | 89 (37) | 149 (32) | 159 (36) | |
| Biopsy grade group, n (%) | 0.453C | ||||
| 1 | 4 (8) | 41 (18) | 76 (16) | 79 (18) | |
| 2 | 10 (20) | 24 (10) | 64 (14) | 51 (12) | |
| 3 | 3 (6) | 23 (10) | 33 (7) | 34 (10) | |
| 4 | 6 (12) | 27 (12) | 71 (15) | 60 (14) | |
| 5 | 22 (43) | 34 (15) | 57 (12) | 69 (16) | |
| Unknown | 34 (39) | 85 (36) | 160 (35) | 137 (32) | |
| PSA at CRPC (ng/mL),Median (Q1–Q3) | 7.5 (3.2–15.1) | 4.4 (3.0–8.3) | 4.7 (3.1–9.5) | 4.6 (3.1–9.4) | 0.228K |
| Developed Metastases, n (%) | 27 (53) | 122 (51) | 273 (59) | 264 (60) | 0.101C |
| Died, n (%) | 37 (73) | 174 (73) | 339 (73) | 298 (68) | 0.353C |
| Died from PC, n (%) | 21 (41) | 97 (41) | 226 (49) | 204 (47) | 0.193C |
| Follow-up (months)#, Median (Q1–Q3) | 28.8 (8.4–44.8) | 30.6 (12.9–56.6) | 36.8 (22.2–65.1) | 35.7 (21.9–58.9) | 0.208K |
P-value calculated using C chi-square test or K Kruskal-Wallis test
#
Reported among patients who did not die